Rapid cardiovascular effects of growth hormone treatment in short prepubertal children: impact of treatment duration
(2012) In Clinical Endocrinology 77(6). p.877-884- Abstract
- Objective Previous studies show that growth hormone (GH) treatment increases cardiac dimensions in short children with GH deficiency (GHD) and has diverse cardiac effects in children with idiopathic short stature (ISS). This study was performed to assess the effect of GH on the cardiovascular system in short children with a broad range of GH secretion and GH sensitivity/responsiveness. Design and patients In this prospective, multicentre study, short prepubertal children diagnosed with isolated GHD (89) or ISS (38) were followed during 2 years of GH treatment. They were randomized to receive either a standard (43 mu g/kg/day) or an individualized GH dose (range 17100 mu g/kg/day) based on GH responsiveness estimated by a prediction model... (More)
- Objective Previous studies show that growth hormone (GH) treatment increases cardiac dimensions in short children with GH deficiency (GHD) and has diverse cardiac effects in children with idiopathic short stature (ISS). This study was performed to assess the effect of GH on the cardiovascular system in short children with a broad range of GH secretion and GH sensitivity/responsiveness. Design and patients In this prospective, multicentre study, short prepubertal children diagnosed with isolated GHD (89) or ISS (38) were followed during 2 years of GH treatment. They were randomized to receive either a standard (43 mu g/kg/day) or an individualized GH dose (range 17100 mu g/kg/day) based on GH responsiveness estimated by a prediction model and distance to target height. Echocardiography, blood pressure and electrocardiography were performed at baseline, 3, 12 and 24 months. Results Left ventricular mass (LVM) indexed to body surface area increased significantly during 2 years of GH treatment in both GHD and ISS irrespective of randomized dose. This change was already apparent at 3 months, when standard deviation scores (SDS) of wall thickness and diameter were increased. At 24 months, left ventricular diameter SDS remained increased, whereas myocardial thickness SDS returned to baseline values. There was no impairment of systolic or diastolic function. There was no correlation with treatment dose and LVM SDS at 24 months. Conclusions Irrespective of GH status, there was a rapid increase in LVM during GH treatment in short children. At 3 months, wall thickness and diameter were increased, whereas only diameter remained increased at 24 months. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3492267
- author
- Nygren, Anders ; Sunnegardh, Jan ; Teien, Dag ; Jonzon, Anders ; Björkhem, Gudrun LU ; Lindell, Sven ; Albertsson-Wikland, Kerstin and Kristrom, Berit
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical Endocrinology
- volume
- 77
- issue
- 6
- pages
- 877 - 884
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000310962800014
- scopus:84869005668
- pmid:22651572
- ISSN
- 1365-2265
- DOI
- 10.1111/j.1365-2265.2012.04456.x
- language
- English
- LU publication?
- yes
- id
- 415d86d8-c5c3-426c-b587-911b6b66f7a5 (old id 3492267)
- date added to LUP
- 2016-04-01 10:32:51
- date last changed
- 2022-01-26 00:22:31
@article{415d86d8-c5c3-426c-b587-911b6b66f7a5,
abstract = {{Objective Previous studies show that growth hormone (GH) treatment increases cardiac dimensions in short children with GH deficiency (GHD) and has diverse cardiac effects in children with idiopathic short stature (ISS). This study was performed to assess the effect of GH on the cardiovascular system in short children with a broad range of GH secretion and GH sensitivity/responsiveness. Design and patients In this prospective, multicentre study, short prepubertal children diagnosed with isolated GHD (89) or ISS (38) were followed during 2 years of GH treatment. They were randomized to receive either a standard (43 mu g/kg/day) or an individualized GH dose (range 17100 mu g/kg/day) based on GH responsiveness estimated by a prediction model and distance to target height. Echocardiography, blood pressure and electrocardiography were performed at baseline, 3, 12 and 24 months. Results Left ventricular mass (LVM) indexed to body surface area increased significantly during 2 years of GH treatment in both GHD and ISS irrespective of randomized dose. This change was already apparent at 3 months, when standard deviation scores (SDS) of wall thickness and diameter were increased. At 24 months, left ventricular diameter SDS remained increased, whereas myocardial thickness SDS returned to baseline values. There was no impairment of systolic or diastolic function. There was no correlation with treatment dose and LVM SDS at 24 months. Conclusions Irrespective of GH status, there was a rapid increase in LVM during GH treatment in short children. At 3 months, wall thickness and diameter were increased, whereas only diameter remained increased at 24 months.}},
author = {{Nygren, Anders and Sunnegardh, Jan and Teien, Dag and Jonzon, Anders and Björkhem, Gudrun and Lindell, Sven and Albertsson-Wikland, Kerstin and Kristrom, Berit}},
issn = {{1365-2265}},
language = {{eng}},
number = {{6}},
pages = {{877--884}},
publisher = {{Wiley-Blackwell}},
series = {{Clinical Endocrinology}},
title = {{Rapid cardiovascular effects of growth hormone treatment in short prepubertal children: impact of treatment duration}},
url = {{http://dx.doi.org/10.1111/j.1365-2265.2012.04456.x}},
doi = {{10.1111/j.1365-2265.2012.04456.x}},
volume = {{77}},
year = {{2012}},
}